Latest news with #HIVDiagnostics
Globe and Mail
22-05-2025
- Health
- Globe and Mail
HIV Diagnosis Market to Hit USD 5.31 Billion by 2030 with 10.3% CAGR
"The major market players involved in this market are Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain), Bio-Rad Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Hologic, Inc. (US), QIAGEN (Germany)" Browse 332 market data Tables and 50 Figures spread through 273 Pages and in-depth TOC on "HIV Diagnostics Market by Product (Assay Kits & Reagents, Instrument, Software), Test Type (Rapid Test, ELISA, Western Blot, Viral Load, CD4 Test), End User (Diagnostic Laboratories, Homecare Settings, Hospital) - Global Forecast to 2030 The global HIV diagnosis market, valued at US$2.96 billion in 2024, is forecasted to grow at a robust CAGR of 10.3%, reaching US$3.25 billion in 2025 and an impressive US$5.31 billion by 2030. The HIV diagnostics market is driven by several key factors, such as the rising prevalence of HIV/AIDS, the increasing number of blood transfusions and blood donations, advantages offered by POC diagnostic kits & instruments, and the growing focus on initiatives for HIV awareness. However, the high cost of nucleic acid testing, operational barriers, and the shortage of skilled laboratory technicians are expected to restrain the market growth to a certain extent. Efforts driven by government health initiatives and public awareness campaigns promoting HIV testing are significantly boosting market growth. Additionally, innovations in testing technologies, such as rapid tests and self-testing kits, along with improved accuracy and ease of use, are enhancing patient compliance and encouraging wider adoption. Despite these positive developments, challenges like the high cost of diagnostic tests and complex testing procedures may slow down growth. However, the market is expected to continue progressing steadily, fueled by a stronger emphasis on early detection, improved healthcare access, and the increasing availability of advanced, convenient testing solutions. Browse in-depth TOC on " HIV Diagnosis Market" 332 - Tables 50 - Figures 273 - Pages Based on product type, the HIV diagnostics market is divided into consumables, instruments and software& services. In 2024, the consumables segment accounted for the largest share of the HIV diagnostics market. The large share and the high growth rate of the consumables segment can be attributed to the frequent & repetitive purchase of consumables by laboratories and hospitals; the growing prevalence of HIV/AIDS; and favorable government initiatives to launch advanced consumables in the market. Based on Test Type, the HIV diagnostics market is segmented into screening tests, confirmatory tests and monitoring tests. The monitoring tests segment accounted for the largest share of the HIV diagnostics market in 2024. This segment is also expected to grow at the highest CAGR owing to the increasing awareness of HIV testing; the high volume of monitoring test samples; and the growing establishment of diagnostic laboratories for testing of HIV/AIDS. Additional factors include technological advancements in monitoring testing kits. Based on end users, the HIV diagnostics market is segmented into diagnostic laboratories, hospitals, blood banks, home cares settings and other end users. The diagnostic laboratories segment accounted for the largest share of the HIV diagnostics market in 2024. The large share of this segment owed to the increasing prevalence of HIV/AIDS; the rising establishment of diagnostic laboratories; growing sample testing; and advancements in PoC instruments. The HIV diagnostics market is segmented into six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America dominates the global market and is expected to continue during the forecast period. Factors such as the rising prevalence of HIV/AIDS, advancements in PoC instruments and kits, increasing awareness about HIV/AIDS, and increasing blood transfusion and blood donations are driving the growth of the HIV diagnostics market in North America. However, the Asia Pacific market is expected to grow at the highest CAGR of 12.5% during the forecast period. The high growth rate of the Asia Pacific market can be attributed to the rising target patient population; the expansion of emerging economies; the increasing availability of technologically advanced POC products; favorable government initiatives for HIV awareness; and the growing expansion of global players in this region. The major market players involved in this market are Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain), Bio-Rad Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Hologic, Inc. (US), QIAGEN (Germany), Becton, Dickinson, and Company (US), Trinity Biotech (Ireland), OraSure Technologies (US), BioSynex SA (Chembio Diagnostics) (France), Wondfo (China), Getein Biotech Inc. (China), Meril Diagnostics (India), AccuBioTech (China), BioLytical Laboratories Inc. (Canada), BioLab Diagnostics (India), Alpine Biomedicals Pvt. Ltd (India), Molbio Diagnostics (India), Fortress Diagnostics (UK), AdvaCare Pharma (US), Adaltis s.r.l (Italy) among others. ABBOTT (US) Abbott is the leading player in the HIV diagnostics market. The company has a strong presence in the US and seeks to enhance its geographical presence by strengthening its business operations in emerging markets. The company has a strong product portfolio, and its FDA- and CE-approved products have helped it gain a sizable market share. Abbott focuses on inorganic growth strategies, such as collaborations and acquisitions, to enhance its product portfolio and expand its geographical presence. The company's extensive research & development activities for product development and its ongoing clinical trials for newly developed products will further enhance its share in the HIV diagnostics market. SIEMENS HEALTHINEERS AG (GERMANY) Siemens Healthineers AG is among the leading players in the global HIV diagnostics market. The company provides a comprehensive portfolio of medical solutions, from medical imaging and in vitro diagnostics to interventional and clinical information technology systems. The company focuses on organic strategies, including product approvals, to enhance its presence in the global POC market. It also aims to create innovative products that address the unmet needs of patients and healthcare providers and take the first-mover advantage. The company also focuses on partnerships and collaborations to enhance its market presence. For instance, in December 2023, Siemens Healthineers AG and OU Health entered a 10-year value partnership to bring the latest diagnostic and therapeutic equipment to people across Oklahoma. THERMO FISHER SCIENTIFIC (US) Thermo Fisher Scientific is a key player in the global HIV diagnostics market, offering a comprehensive range of diagnostic solutions, including PCR-based assays, immunoassays, and molecular testing technologies. The company has a strong presence in developed and emerging markets, leveraging its advanced research capabilities and extensive distribution network. Thermo Fisher focuses on continuous innovation, regulatory approvals, and strategic acquisitions to expand its product portfolio. Additionally, the company collaborates with healthcare organizations and government agencies to enhance diagnostic accessibility and improve early detection of HIV. For more information, Inquire Now!
Yahoo
10-05-2025
- Business
- Yahoo
HIV Diagnostics Market Projected to Hit USD 1.80 Billion by 2032, Driven by Rising Global Testing Rates and Technological Advancements
Increasing awareness, improved healthcare access, and next-gen diagnostic tools fuel steady 5.10% CAGR growth in the HIV diagnostics market through 2032. Austin, May 10, 2025 (GLOBE NEWSWIRE) -- HIV Diagnostics Market Size Analysis: According to SNS Insider, the HIV Diagnostics Market was valued at USD 1.15 billion in 2023 and is set to reach USD 1.80 billion by 2032, growing at a CAGR of 5.10% during the forecast period of 2024–2032 The need for more rapid and readily accessible diagnostic tests has significantly increased as the global HIV count continues to rise. Advances in technology, improved healthcare facilities, and an increased focus on early diagnosis and prevention are largely responsible for this growth. As public support for healthcare grows, the market for HIV diagnostics will evolve substantially in most nations, especially in Asia-Pacific and North a Sample Report of HIV Diagnostics Market@ The U.S. HIV diagnostics market was valued at USD 0.20 billion in 2023 and is expected to reach USD 0.27 billion by the year 2032. This reflects a 3.36% CAGR. Increased diagnosis rates of HIV, increased awareness, and the embrace of improved diagnostic technology are largely to be blamed for this phenomenon. Innovations like in-home HIV diagnostic kits and point-of-care testing facilities keep the United States' market ahead of others in this regard. Major Players Analysis Listed in this Report are: Alere Inc.: Determine HIV-1/2 Ag/Ab Combo Abbott: ARCHITECT HIV Ag/Ab Combo Assay Bristol-Myers Squibb Company: Sustiva (efavirenz) Janssen Global Services, LLC: Prezista (darunavir) Gilead Sciences, Inc.: Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), Sunlenca (lenacapavir) Merck & Co., Inc.: Isentress (raltegravir) ViiV Healthcare: Tivicay (dolutegravir), Triumeq (abacavir/dolutegravir/lamivudine) BD (Becton, Dickinson and Company): BD FACSPresto System Beckman Coulter, Inc.: Access HIV Combo Assay PointCare: PointCare NOW System F. Hoffmann-La Roche Ltd.: COBAS AmpliPrep/COBAS TaqMan HIV-1 Test Siemens Healthcare GmbH: ADVIA Centaur HIV Ag/Ab Combo Assay QIAGEN: artus HIV-1 QS-RGQ Kit OraSure Technologies: OraQuick In-Home HIV Test DiaSorin: LIAISON XL murex HIV Ab/Ag HIV Diagnostics Market Report Scope Report Attributes Details Market Size in 2023 US$ 1.15 billion Market Size by 2032 US$ 1.80 billion CAGR CAGR of 5.10% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Segment Analysis By Product: Comprising a market share of 45.5%, the consumables sector led the HIV diagnostics market in 2023. The great demand for consumable items, reagents, and diagnostic kits used in HIV testing accounts for the predominance of this category. Consumables remain the main source of income, even with the rising number of diagnostic treatments carried out. Conversely, the sector of software and services is predicted to increase the most since the increasing acceptance of digital platforms and AI-based diagnostic tools enhances patient management and testing accuracy, thereby improving the segment. By Mode: With 90.9% of the market share in 2023, the category of laboratory-based testing kept its leading place. Given that laboratory-based tests—which are regarded as the gold standard for HIV diagnosis—have great accuracy and dependability, their supremacy results mostly from their On the other hand, the segment of self-testing is predicted to rise most since need for privacy and convenience lets people test for HIV in the comfort of their homes. The broad availability of at-home testing kits and a move toward decentralization in healthcare services promote this trend. By Test Type: With a 53.6% share of income, the segment of the antibody tests dominated the test category in 2023. The most often used HIV diagnostic test, the antibody tests, are the reason behind this supremacy since they produce consistent and accurate findings in HIV infection detection. Given its rising use in both clinical environments and at-home testing options, where it is considered the first line of HIV detection, the antibody test segment is also expected to increase the most. By End Use: The biggest end-use category in the HIV diagnostics market, the diagnostic labs segment, produced 50.4% of market revenue in 2023. HIV testing is mostly dependent on diagnostic labs since they can offer accurate, high-throughput testing. Driven by the growing availability and simplicity of home testing kits, the sector in home settings is predicted to develop fastest. In areas with high HIV prevalence and restricted access to healthcare infrastructure, this trend is especially noteworthy. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ HIV Diagnostics Market Segmentation By Product Consumables Instruments Software and Services By Mode Self-test Lab-based By Test type Antibody Test HIV-1 Screening Tests HIV-1 Antibody Confirmatory Tests HIV-2 & Group O Diagnostic Tests Viral load test CD4 test Others By End Use Diagnostic Laboratories Hospitals & Clinics Home Settings Recent Developments in HIV Diagnostics In November 2024, Egypt and the Global Fund signed a Framework Agreement aimed at strengthening health systems and improving HIV and tuberculosis response efforts while addressing the ongoing impact of COVID-19. UNDP will coordinate efforts with the Ministry of Health and civil society organizations to enhance HIV prevention and diagnostic services. In April 2024, Cepheid received WHO prequalification for its Xpert HIV-1 Qual XC test. This point-of-care diagnostic test enables early HIV detection in infants using dried blood spots and whole blood samples, thus enhancing accessibility and accuracy in HIV diagnostics, especially in resource-limited settings. In January 2024, Abbott launched the ARCHITECT HIV Ag/Ab Combo test, which provides reliable and rapid detection of HIV infection by identifying both HIV antibodies and antigens. This test aims to improve diagnostic accuracy and accelerate HIV detection in clinical settings. In March 2024, Mylan announced the launch of its generic HIV self-testing kit, which is designed to provide users with a simple, accurate, and confidential method to test for HIV at home. The launch is part of Mylan's broader effort to improve access to affordable HIV diagnostics globally. In February 2024, Roche introduced a new fully automated system for HIV diagnostics, combining antigen and antibody testing for faster and more accurate results. This innovation is expected to improve efficiency in high-throughput testing labs. Regional Analysis North America dominated the HIV diagnostics market in 2023 due to the presence of leading healthcare providers and the high demand for advanced diagnostic solutions. Government initiatives, such as increased funding for HIV awareness and testing programs, have contributed to the market's dominance in the region. Furthermore, the region's well-established healthcare infrastructure and adoption of cutting-edge diagnostic technologies, including self-testing kits and at-home diagnostic tools, continue to drive market growth. Asia Pacific is expected to experience the highest growth from 2024 to 2032. The region has a large HIV-infected population, and increasing government and private sector efforts to combat the disease. Growing awareness, improved access to healthcare services, and the increasing adoption of advanced HIV diagnostics are driving this rapid growth. Statistical Insights and Trends Reporting In 2023, the global incidence of new HIV cases was approximately 1.5 million, with Sub-Saharan Africa accounting for the majority of new infections. North America accounted for the highest share of HIV testing prescriptions, with a growing shift toward self-testing and rapid diagnostic tests. North America and Europe dominated the HIV diagnostics device volume in 2023, while Asia Pacific is expected to show the highest volume growth due to increased testing and awareness. In 2023, government-funded HIV diagnostic programs accounted for 60% of global HIV testing efforts, with the remaining share split between commercial healthcare providers and out-of-pocket expenditures in low-income a Single-User PDF of HIV Diagnostics Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Incidence and Prevalence of HIV (2023) 5.2 HIV Testing and Diagnosis Rates (2023), by Region 5.3 HIV Diagnostic Test Volume, by Region (2020-2032) 5.4 Healthcare Spending on HIV Diagnostics, by Region (Government, Commercial, Private, Out-of-Pocket), 2023 5.5 Adoption of Advanced HIV Diagnostic Technologies (2023-2032) 5.6 Regulatory Approvals and Policy Impact on HIV Diagnostics (2023-2032) 6. Competitive Landscape 7. HIV Diagnostics Market by Product 8. HIV Diagnostics Market by Mode 9. HIV Diagnostics Market by Test type 10. HIV Diagnostics Market by End Use 11. Regional Analysis 12. Company Profiles 13. Use Cases and Best Practices 14. Conclusion Related Reports: Point-of-Care Testing Market Analysis Molecular Diagnostics Market Forecast Immunoassay Analyzers Market Trends STD Diagnostics Market Outlook Rapid Medical Diagnostic Kits Market Overview About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
HIV Diagnostics Market Projected to Hit USD 1.80 Billion by 2032, Driven by Rising Global Testing Rates and Technological Advancements
Increasing awareness, improved healthcare access, and next-gen diagnostic tools fuel steady 5.10% CAGR growth in the HIV diagnostics market through 2032. Austin, May 10, 2025 (GLOBE NEWSWIRE) -- HIV Diagnostics Market Size Analysis: According to SNS Insider, the HIV Diagnostics Market was valued at USD 1.15 billion in 2023 and is set to reach USD 1.80 billion by 2032, growing at a CAGR of 5.10% during the forecast period of 2024–2032 The need for more rapid and readily accessible diagnostic tests has significantly increased as the global HIV count continues to rise. Advances in technology, improved healthcare facilities, and an increased focus on early diagnosis and prevention are largely responsible for this growth. As public support for healthcare grows, the market for HIV diagnostics will evolve substantially in most nations, especially in Asia-Pacific and North a Sample Report of HIV Diagnostics Market@ The U.S. HIV diagnostics market was valued at USD 0.20 billion in 2023 and is expected to reach USD 0.27 billion by the year 2032. This reflects a 3.36% CAGR. Increased diagnosis rates of HIV, increased awareness, and the embrace of improved diagnostic technology are largely to be blamed for this phenomenon. Innovations like in-home HIV diagnostic kits and point-of-care testing facilities keep the United States' market ahead of others in this regard. Major Players Analysis Listed in this Report are: Alere Inc.: Determine HIV-1/2 Ag/Ab Combo Abbott: ARCHITECT HIV Ag/Ab Combo Assay Bristol-Myers Squibb Company: Sustiva (efavirenz) Janssen Global Services, LLC: Prezista (darunavir) Gilead Sciences, Inc.: Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), Sunlenca (lenacapavir) Merck & Co., Inc.: Isentress (raltegravir) ViiV Healthcare: Tivicay (dolutegravir), Triumeq (abacavir/dolutegravir/lamivudine) BD (Becton, Dickinson and Company): BD FACSPresto System Beckman Coulter, Inc.: Access HIV Combo Assay PointCare: PointCare NOW System F. Hoffmann-La Roche Ltd.: COBAS AmpliPrep/COBAS TaqMan HIV-1 Test Siemens Healthcare GmbH: ADVIA Centaur HIV Ag/Ab Combo Assay QIAGEN: artus HIV-1 QS-RGQ Kit OraSure Technologies: OraQuick In-Home HIV Test DiaSorin: LIAISON XL murex HIV Ab/Ag HIV Diagnostics Market Report Scope Report Attributes Details Market Size in 2023 US$ 1.15 billion Market Size by 2032 US$ 1.80 billion CAGR CAGR of 5.10% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Segment Analysis By Product: Comprising a market share of 45.5%, the consumables sector led the HIV diagnostics market in 2023. The great demand for consumable items, reagents, and diagnostic kits used in HIV testing accounts for the predominance of this category. Consumables remain the main source of income, even with the rising number of diagnostic treatments carried out. Conversely, the sector of software and services is predicted to increase the most since the increasing acceptance of digital platforms and AI-based diagnostic tools enhances patient management and testing accuracy, thereby improving the segment. By Mode: With 90.9% of the market share in 2023, the category of laboratory-based testing kept its leading place. Given that laboratory-based tests—which are regarded as the gold standard for HIV diagnosis—have great accuracy and dependability, their supremacy results mostly from their On the other hand, the segment of self-testing is predicted to rise most since need for privacy and convenience lets people test for HIV in the comfort of their homes. The broad availability of at-home testing kits and a move toward decentralization in healthcare services promote this trend. By Test Type: With a 53.6% share of income, the segment of the antibody tests dominated the test category in 2023. The most often used HIV diagnostic test, the antibody tests, are the reason behind this supremacy since they produce consistent and accurate findings in HIV infection detection. Given its rising use in both clinical environments and at-home testing options, where it is considered the first line of HIV detection, the antibody test segment is also expected to increase the most. By End Use: The biggest end-use category in the HIV diagnostics market, the diagnostic labs segment, produced 50.4% of market revenue in 2023. HIV testing is mostly dependent on diagnostic labs since they can offer accurate, high-throughput testing. Driven by the growing availability and simplicity of home testing kits, the sector in home settings is predicted to develop fastest. In areas with high HIV prevalence and restricted access to healthcare infrastructure, this trend is especially noteworthy. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ HIV Diagnostics Market Segmentation By Product Consumables Instruments Software and Services By Mode Self-test Lab-based By Test type Antibody Test HIV-1 Screening Tests HIV-1 Antibody Confirmatory Tests HIV-2 & Group O Diagnostic Tests Viral load test CD4 test Others By End Use Diagnostic Laboratories Hospitals & Clinics Home Settings Recent Developments in HIV Diagnostics In November 2024, Egypt and the Global Fund signed a Framework Agreement aimed at strengthening health systems and improving HIV and tuberculosis response efforts while addressing the ongoing impact of COVID-19. UNDP will coordinate efforts with the Ministry of Health and civil society organizations to enhance HIV prevention and diagnostic services. In April 2024, Cepheid received WHO prequalification for its Xpert HIV-1 Qual XC test. This point-of-care diagnostic test enables early HIV detection in infants using dried blood spots and whole blood samples, thus enhancing accessibility and accuracy in HIV diagnostics, especially in resource-limited settings. In January 2024, Abbott launched the ARCHITECT HIV Ag/Ab Combo test, which provides reliable and rapid detection of HIV infection by identifying both HIV antibodies and antigens. This test aims to improve diagnostic accuracy and accelerate HIV detection in clinical settings. In March 2024, Mylan announced the launch of its generic HIV self-testing kit, which is designed to provide users with a simple, accurate, and confidential method to test for HIV at home. The launch is part of Mylan's broader effort to improve access to affordable HIV diagnostics globally. In February 2024, Roche introduced a new fully automated system for HIV diagnostics, combining antigen and antibody testing for faster and more accurate results. This innovation is expected to improve efficiency in high-throughput testing labs. Regional Analysis North America dominated the HIV diagnostics market in 2023 due to the presence of leading healthcare providers and the high demand for advanced diagnostic solutions. Government initiatives, such as increased funding for HIV awareness and testing programs, have contributed to the market's dominance in the region. Furthermore, the region's well-established healthcare infrastructure and adoption of cutting-edge diagnostic technologies, including self-testing kits and at-home diagnostic tools, continue to drive market growth. Asia Pacific is expected to experience the highest growth from 2024 to 2032. The region has a large HIV-infected population, and increasing government and private sector efforts to combat the disease. Growing awareness, improved access to healthcare services, and the increasing adoption of advanced HIV diagnostics are driving this rapid growth. Statistical Insights and Trends Reporting In 2023, the global incidence of new HIV cases was approximately 1.5 million, with Sub-Saharan Africa accounting for the majority of new infections. North America accounted for the highest share of HIV testing prescriptions, with a growing shift toward self-testing and rapid diagnostic tests. North America and Europe dominated the HIV diagnostics device volume in 2023, while Asia Pacific is expected to show the highest volume growth due to increased testing and awareness. In 2023, government-funded HIV diagnostic programs accounted for 60% of global HIV testing efforts, with the remaining share split between commercial healthcare providers and out-of-pocket expenditures in low-income a Single-User PDF of HIV Diagnostics Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Incidence and Prevalence of HIV (2023) 5.2 HIV Testing and Diagnosis Rates (2023), by Region 5.3 HIV Diagnostic Test Volume, by Region (2020-2032) 5.4 Healthcare Spending on HIV Diagnostics, by Region (Government, Commercial, Private, Out-of-Pocket), 2023 5.5 Adoption of Advanced HIV Diagnostic Technologies (2023-2032) 5.6 Regulatory Approvals and Policy Impact on HIV Diagnostics (2023-2032) 6. Competitive Landscape 7. HIV Diagnostics Market by Product 8. HIV Diagnostics Market by Mode 9. HIV Diagnostics Market by Test type 10. HIV Diagnostics Market by End Use 11. Regional Analysis 12. Company Profiles 13. Use Cases and Best Practices 14. Conclusion Related Reports: Point-of-Care Testing Market Analysis Molecular Diagnostics Market Forecast Immunoassay Analyzers Market Trends STD Diagnostics Market Outlook Rapid Medical Diagnostic Kits Market Overview About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
